Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Celldex Therapeutics (CLDX) is trading at $32.59, up 2.97% on the day. Its market value of $2.56B makes it the 2602nd largest of the 3132 companies we follow.
Over a full year the shares have ranged across $22.10 to $45.14, which puts the current price roughly 46% of the way up that band. Holders are ahead 23.5% over twelve months, but down 18.4% across the last three months.
Price is below the 50-day average ($38.23) but above the 200-day ($32.36); RSI is 37, and the last 30 sessions moved at roughly 50% annualized volatility.
10 analysts follow the stock and the average call is "buy". The mean target, $68.70, sits 110.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3131 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
10 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
CLDX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $68.70, 110.8% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $31.49, so shares trade 3.5% above that estimate. On earnings multiple, it sits in the 92nd percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -7.4% | Bearish |
| Price vs 50-day average | -14.8% | Bearish |
| Price vs 200-day average | +0.7% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 36.5 | Bearish |
| MACD (12,26,9) | -2.01 | Bearish |
| Bollinger band position | 31% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 6, 2026 4:20 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,131 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$32.59 is the latest print for CLDX, a move of +2.97% against yesterday's close of $31.65. Today's low and high so far: $31.50 and $32.88.
Equity value comes to $2.56B at the current price. By that measure it is number 2602 of the 3132 names in our coverage.
The year's floor is $22.10 and the ceiling $45.14. Shares are 27.8% away from that ceiling.
Our data shows no dividend paid by Celldex Therapeutics over the trailing twelve months.
Of 10 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $68.70, with the most cautious at $53.00 and the most optimistic at $100.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on CLDX.